Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.

Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, miR-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, miR-374b-5p, miR-615-3p and miR-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.

Abstract: A computing system may receive an encoded representation of a biological sample. The encoded representation may contain an embedded barcode, and the computing system may include locked features. Possibly based on the embedded barcode, the computing system may automatically select a data processing pipeline for the encoded representation. Also possibly based on the embedded barcode, the computing system may unlock one or more of the locked features. The computing system may process the encoded representation in the selected data processing pipeline and according to the one or more unlocked features.

Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.

Abstract: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK signalling pathway in a patient. Moreover the present invention relates to a method of treatment, and a method of detecting the activity of compounds, in particular drug candidates, that interact with the FVIIa mediated intracellular signalling pathway.

Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236-242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236-242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236–242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Abstract: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK signalling pathway in a patient. Moreover the present invention relates to a method of treatment, and a method of detecting the activity of compounds, in particular drug candidates, that interact with the FVIIa mediated intracellular signalling pathway.

Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.

Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

Abstract: The present invention provides methods for high-temperature biopreparation of cellulosic fibers by contacting the fibers with pectin-degrading enzymes, preferably thermostable, alkaline, divalent cation-independent pectate lyases, under conditions compatible with scouring and bleaching technologies.

Abstract: The invention relates to a ellulose film comprising microfibrillated cellulose and to the use of it for screening of a biological compound and nucleic acids encoding a biological compound.